The FDA posted a warning letter Tuesday that cited contamination problems with sterile drugs at a Pfizer Inc. plant that's expected to delay approval of a Copaxone (glatiramer acetate, Teva Pharmaceutical Industries Inc.) 40-mg generic developed by Momenta Pharmaceuticals Inc. and Sandoz Inc.